Abivax S.A. (ABVX) research
Abivax S.A.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $98.29
- As of
Abivax S.A. (ABVX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-21.
As of . Source: SEC EDGAR filings for ABVX. Method and limitations.
Share the ABVX intelligence card
See ABVX live in the terminal
Track ABVX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ABVX terminal, freeActive signals for ABVX
- highCONSENSUS_BUY
7 tracked funds increased ABVX this 2026Q2, institutional consensus
- highCONSENSUS_SELL
3 tracked funds reduced ABVX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased ABVX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 92% of ABVX (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +742% to ABVX (2026Q2)
FREE, NO ACCOUNT
Every signal on ABVX, as it fires
You are seeing 5 of 45 signals recorded on ABVX since 2026-05-16.
The five above landed across 2 days. The other 40 were recorded on 3 other days. 37 of the 45 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ABVX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 00370M103 · 2026Q2 | $191.7M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00370M103 · 2026Q2 | $31.1M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 00370M103 · 2026Q2 | $12M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 00370M103 · 2026Q2 | $670K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABVX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
ABVX against its peers
ABVX's return on equity of -73.8% ranks in the 17th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | ABVX | Peer median | Percentile | n |
|---|---|---|---|---|
| Operating margin | n/a | -101.2% | n/a | 15 |
| Net margin | n/a | -103.6% | n/a | 15 |
| Return on equity | -73.8% | -21.5% | 17 | 20 |
Peers (23): PCVX, PRAX, IBRX, CRNX, TGTX, SYRE, KYMR, CAI, PTGX, CYTK, ALKS, NUVL, IMVT, ARWR, KRYS, IONS, APGE, RYTM, BLTE, CGON, SRRK, MIRM, CNTA. Left out: BCHMY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ABVX: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ABVX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ABVXand get the insider, 13F, options, and confluence read in one view.